Oxford BioDynamics (LON:OBD) Reaches New 12-Month Low – What’s Next?

Oxford BioDynamics Plc (LON:OBD) hit a new 52-week low on Tuesday . The company traded as low as GBX 0.23 and last traded at GBX 0.24, with a volume of 57837910 shares. The stock had previously closed at GBX 0.25.

Analysts Set New Price Targets

Separately, Shore Capital reaffirmed a “house stock” rating on shares of Oxford BioDynamics in a report on Wednesday, October 8th.

Oxford BioDynamics Trading Down 4.8%

The stock has a 50 day moving average of GBX 0.34 and a 200 day moving average of GBX 0.41. The company has a debt-to-equity ratio of 370.22, a current ratio of 0.68 and a quick ratio of 2.80. The firm has a market cap of £10.21 million, a P/E ratio of -0.08 and a beta of 0.42.

About Oxford BioDynamics

Oxford BioDynamics Plc is a global biotechnology company, advancing personalized healthcare by developing and commercializing precision medicine tests for life-changing diseases.

Its flagship product is EpiSwitch® CiRT (Checkpoint Inhibitor Response Test) for cancer, a predictive immune response profile for immuno-oncology (IO) checkpoint inhibitor treatments, launched in February 2022.

In March 2021, the Company launched its first commercial prognostic test, EpiSwitch® CST (Covid Severity Test) and the first commercially available microarray kit for high-resolution 3D genome profiling and biomarker discovery, EpiSwitch® Explorer Array Kit.